Cryptococcosis - Pipeline Review, H2 2020

August 2020 | 59 pages | ID: C4666D2DC7AEN
Global Markets Direct

Abstracts

Cryptococcosis - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cryptococcosis - Pipeline Review, H2 2020, provides an overview of the Cryptococcosis (Infectious Disease) pipeline landscape.

Cryptococcosis is infection caused by Cryptococcus neoformans fungus. Symptoms include cough, fatigue, fever, head ache, nausea and skin rashes. Predisposing factors are most often seen in people with a weakened immune system, such as those with HIV infection, taking high doses of corticosteroid medications, cancer chemotherapy, or who have Hodgkin's disease. Treatment includes anti fungal drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cryptococcosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cryptococcosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cryptococcosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cryptococcosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Cryptococcosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Cryptococcosis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Cryptococcosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Cryptococcosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Cryptococcosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Cryptococcosis (Infectious Disease)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Cryptococcosis (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Cryptococcosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Cryptococcosis - Overview
Cryptococcosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cryptococcosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cryptococcosis - Companies Involved in Therapeutics Development
Amplyx Pharmaceuticals Inc
Amtixbio Co Ltd
Basilea Pharmaceutica Ltd
Collaborations Pharmaceuticals Inc
iNtRON Biotechnology Inc
Mycovia Pharmaceuticals Inc
Novabiotics Ltd
Pulmocide Ltd
Visterra Inc
Cryptococcosis - Drug Profiles
APX-2039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Cryptococcosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cryptococcosis - Dormant Projects
Cryptococcosis - Discontinued Products
Cryptococcosis - Product Development Milestones
Featured News & Press Releases
Sep 09, 2019: FDA grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for seven different indications
Feb 11, 2019: FDA grants orphan drug designation to Amplyx Pharmaceuticals for APX001 for treatment of cryptococcosis
Apr 18, 2018: Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole
Mar 12, 2018: Amplyx Pharmaceuticals Receives Fourth Qualified Infectious Disease Product Designation from the FDA for APX001
Jun 27, 2016: New Promise Against Deadly Global Fungal Infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Cryptococcosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Cryptococcosis - Pipeline by Amplyx Pharmaceuticals Inc, H2 2020
Cryptococcosis - Pipeline by Amtixbio Co Ltd, H2 2020
Cryptococcosis - Pipeline by Basilea Pharmaceutica Ltd, H2 2020
Cryptococcosis - Pipeline by Collaborations Pharmaceuticals Inc, H2 2020
Cryptococcosis - Pipeline by iNtRON Biotechnology Inc, H2 2020
Cryptococcosis - Pipeline by Mycovia Pharmaceuticals Inc, H2 2020
Cryptococcosis - Pipeline by Novabiotics Ltd, H2 2020
Cryptococcosis - Pipeline by Pulmocide Ltd, H2 2020
Cryptococcosis - Pipeline by Visterra Inc, H2 2020
Cryptococcosis - Dormant Projects, H2 2020
Cryptococcosis - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cryptococcosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Amplyx Pharmaceuticals Inc
Amtixbio Co Ltd
Basilea Pharmaceutica Ltd
Collaborations Pharmaceuticals Inc
iNtRON Biotechnology Inc
Mycovia Pharmaceuticals Inc
Novabiotics Ltd
Pulmocide Ltd
Visterra Inc